Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007 |
| |
| Affiliation: | 1. Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK;2. Norwegian Institute of Public Health, Oslo, Norway;3. Agence de Médecine Préventive, Paris, France;4. Ecole des Hautes Etudes en Santé Publique, Rennes/Paris, France and Institut Pasteur, Paris, France;5. Vaccine Evaluation Unit, Public Health England, Manchester, UK;6. Division of Epidemiology, Ministry for Health, Togo;7. Institute National d’Hygiene, Lome, Togo;8. Department of Primary Care and Public Health, Imperial College, London, UK;1. Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA;2. Department of Geriatrics, the Second Hospital of Central South University Medical School, Changsha, Hunan Province, China;3. Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA;4. Biostatistics, Epidemiology, and Database (BEAD) Core; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA;1. Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Hajipur, Bihar, India;2. Division of Molecular Biology, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS), Indian Council of Medical Research, Patna, Bihar, India;3. Department of Microbiology, All India Institute of Medical Sciences, Patna, Bihar, India;1. Department of Radiology, Obafemi Awolowo College of Health Sciences, Olabisi Onabanjo University, Sagamu, Ogun State, Nigeria;2. Department of Haematology and Blood Transfusion Services, Obafemi Awolowo College of Health Sciences, Olabisi Onabanjo University, Sagamu, Ogun State, Nigeria;3. Department of Community Medicine and Primary Care, Obafemi Awolowo College of Health Sciences, Olabisi Onabanjo University, Sagamu, Ogun State, Nigeria;1. Department of Pharmaceutical Sciences, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73126-0901, United States;2. RTI International, 3040 Cornwallis Road, P.O. Box 12194, Research Triangle Park, NC 27709-2194, United States;1. Departamento de Imunologia do Instituto Adolfo Lutz, Av. Dr. Arnaldo 355, 11 Andar, 01246902, São Paulo, SP, Brazil;2. Programa de Pós-Graduação Interunidades em Biotecnologia, Instituto de Ciências Biomédicas, USP, São Paulo, SP, Brazil |
| |
| Abstract: | BackgroundCapsular group X N. meningitidis (MenX) has emerged as a cause of localized disease outbreaks in sub-Saharan Africa, but the human immune response following exposure to MenX antigens is poorly described. We therefore assessed the natural immunity against MenX in individuals who were living in an area affected by a MenX outbreak during 2007 in Togo, West Africa. During 2009, 300 healthy individuals (100 aged 3–5 years, 100 aged 13–19 years and 100 aged 20–25 years) were included in the study, and serum responses were compared with sera from age-matched controls from the U.K. and Burkina Faso.MethodsMenX serum bactericidal antibody (SBA) was measured using rabbit complement, and antibodies against MenX polysaccharide (XPS) and outer membrane vesicles (XOMVs) were quantified by ELISA.ResultsThe proportion of Togolese individuals with an SBA titer of ≥8 against the MenX strain was 29% (95% confidence interval (CI) 18–41) among those aged 3–5 years, 34% (95% CI 9–60) among those aged 13–19 years and 32% (95% CI 24–40) among those aged 20–25 years. These were significantly higher than observed in the control populations from the U.K (range 13–16%) and Burkina Faso (range 2–6%).ConclusionIn Togolese individuals, the concentration of serum IgG against XPS was higher among the two older age groups as compared to the youngest age group. Antibody concentrations against MenX PS correlated significantly with SBA titers. This supports further development of a MenX PS based conjugate vaccine. Further studies are needed to verify the ability of MenX PS to induce SBA in humans. |
| |
| Keywords: | Meningococcal Capsular group X Polysaccharide Bactericidal Antibodies |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
